Clinical Trials Browser

Phase 2 × Recurrence × Decitabine × Clear all

NCT06686108 2025-05-07

Demethylating Agents Combined With Venetoclax for High-risk T-cell Lymphoblastic Lymphoma/Leukemia Post-Transplant Relapse Prevention

Phase 2 Recruiting

LymphoidOther hematologic neoplasm

Leukemia, Recurrence, Precursor T-Cell Lymphoblastic Leukemia-Lymphoma

NCT06316960 2024-08-22

Safety and Efficacy of Avapritinib in Relapsed or Refractory Pediatric CBF-AML With KIT Mutation

Phase 2 Recruiting

Other hematologic neoplasm

Recurrence, Leukemia, Myeloid, Acute

NCT05983276 2024-02-08

Decitabine and Selinexor in Combination to Reverse Drug Resistance With Standard Chemotherapy in Ovarian Cancer

Phase 2 Recruiting

Ovarian Neoplasms, Recurrence

NCT05816746 2023-05-09

Decitabine and Anti-PD-1 in R/R DLBCL

Phase 2 Unknown

Extranodal Extension, Recurrence, Lymphoma, Large B-Cell, Diffuse

NCT03063203 2022-06-02

Single Agent Decitabine in TP53 Mutated Relapsed/Refractory Acute Myeloid Leukemia

Phase 2 Terminated

17 enrolled 20 charts

Other hematologic neoplasm

Recurrence, Leukemia, Myeloid, Acute

NCT05137886 2021-12-17

PD-1 Inhibitor Combined With Decitabine Followed by ASCT as Second-line Therapy for Relapsed or Refractory Classic Hodgkin's Lymphoma

Phase 2 Unknown

Hodgkin Disease, Recurrence

NCT03250962 2019-04-01

SHR-1210 Alone or in Combination With Decitabine in Relapsed or Refractory Hodgkin Lymphoma

Phase 2 Unknown

Hodgkin Disease, Recurrence

NCT03771222 2018-12-13

Prophylactic Donor Lymphocyte Infusion After Allo-PBSCT for Patients With Very High-risk Hematologic Malignancies

Phase 2 Unknown

Graft vs Host Disease, Recurrence